Datacentrex begins energizing 500+ miners; online Scrypt hashrate to rise ~21% to 52.2 TH/s

Datacentrex started energizing over 500 ElphaPex DG2 Scrypt ASIC miners, expecting a 21% increase in online Scrypt hashrate to 52.2 TH/s. The company's total installed fleet exceeds 3,500 miners across four U.S. facilities, with power capacity projected to grow from 12.5 MW to 14 MW. According to the company's SEC filing.

Original reporting
Published Oct 14, 2026, 12:33 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 14, 2026, 12:41 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Datacentrex begins energizing 500+ miners; online Scrypt hashrate to rise ~21% to 52.2 TH/s — source image
Decision brief

The 30-second read

$DTCXNeutralLow
01

Why it matters

The deployment expands the company's mining capacity by roughly 21%, increasing its ability to generate mining revenue and improve asset utilization.

02

Market read

Operational expansion news for a niche crypto‑mining firm; modest relevance for traders focused on crypto‑related equities.

03

What to watch

Potential power cost increases and regulatory scrutiny of crypto mining could offset capacity gains.

Relevance 4/10Novelty 4/10Timing: same day filing

Background

Datacentrex Inc. (ticker DTCX) filed an 8‑K announcing the start of energizing over 500 ElphaPex DG2 Scrypt ASIC miners across four U.S. data centers.

Company-level read

Ticker impact

$DTCXNeutralMedium confidence
Context

SEC 8‑K filing reports Datacentrex beginning energization of 500+ Scrypt ASIC miners, raising online hashrate by ~21% to 52.2 TH/s.

Expected impact

potential modest upside as market prices in higher hash‑rate capacity, but impact limited by small scale.

Evidence & confidence

The deployment adds ~9 TH/s, a modest increase relative to the company's overall hash‑rate; investors may view it positively but the effect is likely limited.

Market effects

Slightly raises overall Scrypt mining supply, could marginally affect hash‑rate pricing dynamics.

U.S. colocation facilities see modest capacity utilization increase.

Limited; impact confined to niche Scrypt mining segment.

Counterpoint

The added hash‑rate may not translate into revenue if cryptocurrency prices stay weak or mining difficulty rises.

Key entities

  • Datacentrex Inc.

    U.S. crypto mining and colocation provider.

  • ElphaPex DG2

    Scrypt ASIC miner model being deployed.

Related articles

$DTCXMed

Datacentrex Reports Third Quarter 2026 Results and $30 Million Investment in Eagle LNG

Datacentrex, Inc. (DTCX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Datacentrex Reports Third Quarter 2026 Results and $30 Million Investment in Eagle LNG Eagle LNG’s established customer base and space propulsion capabilities create additional growth opportunities heading into 2027 ● Reports positive third-quarter Adjusted EBITDA of

$DTCXMed

Datacentrex Reports Second Quarter 2026 Financial Results

Datacentrex, Inc. (DTCX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Datacentrex Reports Second Quarter 2026 Financial Results; Ends Quarter with $51.9 Million in Cash and No Debt ● Revenue of $1.9 million and positive gross profit despite higher power costs and challenging digital asset market conditions ● GAAP net loss of $5.5 milli

$MBRXMedAI 8/10

Moleculin Biotech, Inc. (MBRX): Preclinical Data Show Annamycin Makes Pancreatic Cancer Responsive to Checkpoint Inhibitors, Opening a Combination Path with Immunotherapies

Moleculin Biotech, Inc. (MBRX) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Preclinical Data Show Annamycin Makes Pancreatic Cancer Responsive to Checkpoint Inhibitors, Opening a Combination Path with Immunotherapies Inhibition of CD8+ T cells shortens survival in Annamycin-treated mice, demonstrating the immune system is a functional contri

$BMYMedAI 9/10

Mavacamten Benefit Holds at 56 Weeks in Adolescents With oHCM

Bristol Myers Squibb's mavacamten (Camzyos) showed sustained benefits in adolescents with oHCM at 56 weeks, per SCOUT-HCM trial data. Patients maintained reduced LVOT obstruction, with no LVEF below 50%. The FDA approved mavacamten for pediatric oHCM in September 2026. The drug is available only through the Camzyos REMS Program, requiring echocardiographic monitoring and dose adjustments.